{
    "organizations": [],
    "uuid": "2a440dcaf5607aeebb82dd79079891f182288da6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-fda-accepts-new-drug-application-f/brief-fda-accepts-new-drug-application-for-duvelisib-and-grants-priority-review-idUSASC09V7B",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Accepts New Drug Application For Duvelisib And Grants Priority Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9, 2018 / 7:04 AM / Updated 39 minutes ago BRIEF-FDA Accepts New Drug Application For Duvelisib And Grants Priority Review Reuters Staff \nApril 9 (Reuters) - Verastem Inc: \n* FDA ACCEPTS NEW DRUG APPLICATION FOR DUVELISIB AND GRANTS PRIORITY REVIEW \n* ‍FDA TARGET ACTION DATE IS OCTOBER 5, 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-04-09T10:02:00.000+03:00",
    "crawled": "2018-04-09T10:54:05.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "accepts",
        "new",
        "drug",
        "application",
        "duvelisib",
        "grant",
        "priority",
        "review",
        "reuters",
        "staff",
        "april",
        "reuters",
        "verastem",
        "inc",
        "fda",
        "accepts",
        "new",
        "drug",
        "application",
        "duvelisib",
        "grant",
        "priority",
        "review",
        "target",
        "action",
        "date",
        "october",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}